Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp
British Journal of Dermatology Feb 18, 2018
Stockfleth E, et al. - The experts evaluated the efficacy of ingenol mebutate 0·015% gel (IngMeb) and diclofenac sodium 3% gel (DS) in the treatment of actinic keratosis (AK) on the face or scalp. In the IngMeb group, twice as many patients were noted to be completely clear of AKs when compared to the DS group. More AKs had partially cleared up, if not disappeared completely and the total number presented a notable decrease, in the IngMeb group. Mild or moderate side effects, most commonly redness, was noted at the site of application of any one of the gels.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries